Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

INSP Feb 2022 190.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
68.200.00 (0.00%)
As of 07:01AM EST. Market open.
Advertisement
Full screen
Previous Close68.20
Open68.20
Bid37.40
Ask39.70
Strike190.00
Expire Date2022-02-18
Day's Range68.20 - 68.20
Contract RangeN/A
Volume1
Open Interest1
  • GuruFocus.com

    Valeo Financial Advisors, LLC Buys Vanguard S&P 500 ETF, Vanguard Intermediate-Term ...

    Investment company Valeo Financial Advisors, LLC (Current Portfolio) buys Vanguard S&P 500 ETF, Vanguard Intermediate-Term Government Bond ETF, Merchants Bancorp, SPDR SERIES TRUST, Midland States Bancorp Inc, sells Vanguard FTSE Emerging Markets ETF, iShares MSCI Emerging Markets ETF, Convey Health Solutions Holdings Inc, Republic Bancorp Inc, Alibaba Group Holding during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Valeo Financial Advisors, LLC.

  • GlobeNewswire

    Inspire Medical Systems, Inc. to Report Fourth Quarter and Fiscal 2021 Financial Results on February 8, 2022

    MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced that it will release financial results for the fourth quarter and year ended December 31, 2021 after the close of trading on Tuesday, February 8. Inspire’s management team will host a corresponding conference call

  • GlobeNewswire

    Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2021

    MINNEAPOLIS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) ("Inspire"), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the quarter and full year ended December 31, 2021. Preliminary, Unaudited Revenue and Recent Business Highlights: Revenue for the fourth quarter of 2021 is anticipated to

Advertisement
Advertisement